Correlation Between Acrivon Therapeutics, and Inhibrx
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Inhibrx, you can compare the effects of market volatilities on Acrivon Therapeutics, and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Inhibrx.
Diversification Opportunities for Acrivon Therapeutics, and Inhibrx
0.06 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Acrivon and Inhibrx is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Inhibrx go up and down completely randomly.
Pair Corralation between Acrivon Therapeutics, and Inhibrx
Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Inhibrx. In addition to that, Acrivon Therapeutics, is 1.47 times more volatile than Inhibrx. It trades about -0.07 of its total potential returns per unit of risk. Inhibrx is currently generating about -0.04 per unit of volatility. If you would invest 1,610 in Inhibrx on August 30, 2024 and sell it today you would lose (65.00) from holding Inhibrx or give up 4.04% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Acrivon Therapeutics, Common vs. Inhibrx
Performance |
| Timeline |
| Acrivon Therapeutics, |
| Inhibrx |
Acrivon Therapeutics, and Inhibrx Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Acrivon Therapeutics, and Inhibrx
The main advantage of trading using opposite Acrivon Therapeutics, and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.| Acrivon Therapeutics, vs. Ikena Oncology | Acrivon Therapeutics, vs. Eliem Therapeutics | Acrivon Therapeutics, vs. HCW Biologics | Acrivon Therapeutics, vs. Tempest Therapeutics |
| Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |